LivingGLP1
Study S000131

Tirzepatide With Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer in Overweight and Obese Women

ClinicalTrials.gov record

Registration

Registration
NCT07349641
Study type
INTERVENTIONAL
Phase
PHASE2
Masking
NONE
Status
NOT_YET_RECRUITING
Enrollment
55
Start
2026-11-01
Primary completion
2029-10-31
Lead sponsor
National Cancer Institute (NCI)
Conditions
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions
OTHER:Medical Device Usage and Evaluation; DRUG:Tirzepatide
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
REGISTRY:NCI-2026-00081; OTHER:MDA24-19-01; NIH:P30CA016672; NIH:UG1CA242609

Registered primary outcomes

  • Weighted pathological complete response (pCR) [At 26 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.